MILLS ROBERT S 4
4 · TFF Pharmaceuticals, Inc. · Filed Jan 20, 2021
Insider Transaction Report
Form 4
MILLS ROBERT S
Director
Transactions
- Exercise/Conversion
Common Stock
2021-01-19$2.50/sh+55,100$137,750→ 71,080 total - Sale
Common Stock
2021-01-20$20.20/sh−12,600$254,520→ 15,980 total - Exercise/Conversion
Stock Options (Right to Buy)
2021-01-20−12,600→ 152,019 totalExercise: $2.50From: 2019-09-26Exp: 2028-09-26→ Common Stock (12,600 underlying) - Exercise/Conversion
Common Stock
2021-01-20$2.50/sh+12,600$31,500→ 28,580 total - Exercise/Conversion
Stock Options (Right to Buy)
2021-01-19−55,100→ 164,619 totalExercise: $2.50From: 2019-09-26Exp: 2028-09-26→ Common Stock (55,100 underlying) - Sale
Common Stock
2021-01-19$19.56/sh−55,100$1,077,756→ 15,980 total
Footnotes (3)
- [F1]The transactions reported by this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020.
- [F2]The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.
- [F3]36,005 shares of common stock vested on September 26, 2019 and the remainder of the shares vested at an approximate rate of 9,001 every three months thereafter.